Additionally, MEG3 is downregulated in multiple myeloma where it acts as an endogenous competitive RNA with miR-181a, inhibiting tumor progression and possibly regulating HOXA11 by sponging miR-171a (105). The gene discussed is HOXA11; the disease is plasma cell myeloma.